Background: Using data from an observational study in which the effectiveness of a guideline for eradication of methicillin-resistant Staphylococcus aureus (MRSA) carriage was evaluated, we identified variables that were associated with treatment failure.
Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) has become endemic in healthcare institutions worldwide, with proportions of resistance among invasive S. aureus infections up to 70%, 1 -4 and most of these patients are colonized prior to infection. 5 Carriage of MRSA is associated with a higher risk of infection than carriage of methicillin-susceptible S. aureus (MSSA). 6 Eradication of MRSA carriage may serve two purposes; prevention of infection and prevention of transmission. Several eradication strategies have been proposed, but, to date, the optimal treatment schedule has not been defined. 7 A guideline for the treatment of carriage has been developed by the Dutch Working Party on Antibiotic Policy [Stichting Werkgroep Antibiotica Beleid (SWAB)], based on a systematic literature review and expert opinions. 8 The guideline focuses on a distinction in treatment between uncomplicated and complicated carriage (the latter including MRSA infection, skin lesions, foreign-body material, mupirocin resistance and/or exclusive extranasal carriage), based mainly on expert opinion. 7, 8 The effectiveness of this guideline has been evaluated in an observational study of 613 patients. 9 In short, 60% of MRSA carriers were successfully decolonized after the first eradication attempt and 62% were treated according to the guideline, which was associated with increased treatment success. Using the same study cohort, we identified patient-related, environmental and strainrelated characteristics associated with treatment failure, in order to improve guideline recommendations.
Methods
We conducted a multicentre prospective observational cohort study between 1 October 2006 and 1 October 2008 of patients with MRSA colonization in whom decolonization treatment was started. 9 In total, 18 medical centres distributed throughout the Netherlands participated-5 university hospitals, 11 general teaching hospitals and 2 regional laboratories. Details of this study have been described elsewhere. 9 For the purpose of the present study, data from the cohort study were analysed by means of a multivariate model. Excluded from the analysis were those who started therapy but appeared culture negative at the start of treatment and those who did not complete three follow-up cultures.
Effective eradication after completion of treatment was defined as three consecutive negative sets of surveillance cultures (from nose, throat, perineum and other sites on clinical indication) obtained at least 48 h after completion of treatment and distributed over a period of at least 7 days.
Swabs were obtained from nose, throat and (most of the time) perineum in all patients and from other sites (sputum, urine, skin lesions, catheter exit sites, blood etc.) on indication, both at the time of screening and during follow-up of treatment. In four hospitals, screening swabs from the nose and throat with or without perineum were pooled, and additional site-specific cultures were obtained if the pooled sample grew MRSA.
Since the method of genotyping changed during the study period from PFGE analysis to Staphylococcus protein A gene (spa) typing, we translated the PFGE type into the spa type (http://www.rivm.nl/earss) and pooled the spa types into seven common multilocus sequence types (MLSTs) and a rest group (http://spaserver2.ridom.de). ST398 was considered animal related.
10
The study was approved by the Institutional Review Boards of all participating hospitals.
Statistical analysis
For a reasonable analysis of potential predictors of treatment failure we aimed to include 400 MRSA carriers starting eradication treatment, assuming 25% treatment failure and a final model containing 10 variables of significant importance. The variables included in the multivariate analysis were age, gender, source of MRSA, site(s) of colonization, profession (healthcare worker versus non-healthcare worker), risk factors of carriage (diabetes mellitus, haemodialysis or peritoneal dialysis), chronic or residual upper airway (ear-nose-throat) disease, chronic pulmonary disease, immunocompromised state (e.g. malignancy or HIV) or activities of daily living (ADL) dependency (according to the opinion of the treating physician), risk factors of persistent carriage at the time of decolonization [skin lesions (e.g. eczema and wounds), devices (e.g. catheters and external fixators) and infections with MRSA], MRSA carriage within a household, genotype and susceptibility profile (mupirocinsusceptible versus resistant) of the MRSA strain, details of eradication treatment and if treatment was according to the guideline.
Descriptive statistics for baseline demographic and clinical variables are presented elsewhere; 9 for the subgroup of patients treated according to the guideline, data are presented here. Univariate analysis was done using Fisher's exact tests to compare dichotomous variables, logistic regression to compare categorical variables and a Mann-Whitney U-test to compare age as a continuous variable. Multivariate logistic regression analysis was performed to assess the relationship of predictor variables of interest for treatment failure (i) of the first decolonization course, (ii) stratified for complicated, uncomplicated and unknown complexity of carriage, (iii) in carriers treated according to the guideline only and (iv) 3 months after the first course. We used the Akaike's Information Criterion (AIC) to determine the model with the best fit of the data (i.e. the model with the lowest AIC value).
11 Effect modification was examined by using clinically important interaction terms. Before analysis, predictor variables were assessed for the presence of co-linearity, and, if deemed appropriate, decisions were made to exclude variables from the model. Missing data were replaced by a dummy co-variable for the categories sites of colonization and genotype to impute missing confounder values. We were therefore able to report analyses for the same number of carriers for both crude and adjusted analyses. We did a sensitivity analysis to investigate the effect of these missing data by imputing all variables, but not exposure and outcome data (n ¼613), and by use of a complete case-only analysis (n¼475), which restricted the analysis to participants with complete data about all exposure, outcome and confounder variables. If results are comparable we do not present data of the complete case-only analysis. If specific sites of carriage could not be distinguished, as screening samples had been pooled without additional site-specific cultures, and no other complicating variable was present, complexity of carriage could not be determined. This patient group is analysed separately.
Results are presented as an adjusted odds ratio (OR a ) with 95% confidence interval (CI). For interpretation of the final model results, tests of significance were two-tailed, and P values of ≤0.05 were considered significant. All analyses were carried out using SPSS version 15.0 (SPSS, Chicago, IL, USA) and R version 2.8.0.
Results

Baseline characteristics
Baseline characteristics have been described in detail elsewhere. 9 In brief, of the 613 carriers that received eradication treatment, 333 (54%) carriers were considered complicated at the time of first treatment, mainly because of skin lesions [153/333 (46%)] or non-nasal carriage [165/333 (50%)]. Specific sites of carriage could not be distinguished in 133 carriers (22%), as screening samples had been pooled. In 83 of these 133 carriers, no other Successful eradication of MRSA in carriers complicating variable was present, and therefore the complexity of carriage could not be determined. In the remaining 197 (32%) carriers, carriage was considered uncomplicated. The first treatment was successful in 367 (60%) carriers. Success rates were 61% (120/197), 56% (185/333) and 75% (62/83) (P ¼ 0.07), respectively, for uncomplicated carriage, complicated carriage and unknown complexity of carriage (unknown nasal carriage status). Sixty-two percent (327/530) of carriers for whom complexity of carriage was available were treated according to the guideline; success rates were higher among those treated according to the guideline versus those who were not [214/327 (65%) versus 91/203 (45%); P,0.001]. Guideline adherence increased the absolute likelihood of treatment success 20% (95% CI 12% -28%). Baseline characteristics of the 327 study participants who were treated according to the guideline are listed in Table 1 .
Predictors of failure of decolonization treatment
In the multivariate analysis of 613 carriers who underwent a decolonization attempt, the following variables were independently associated with failure of the first eradication treatment: chronic pulmonary disease (OR a 5.1, 95% CI 1. Table 2 ). The same variables were significantly associated with treatment outcome in a complete case-only analysis to investigate the effect of missing data and at 3 months after the start of first treatment, except for the addition of another topical treatment (data not shown). A subgroup analysis of patients that were treated according to the guideline did not substantially change the effect estimates of the model. After stratification for the type of carriage, chronic pulmonary disease (OR a 44, 95% CI 2.9-668), ADL dependency (OR a 5.5, 95% CI 1.0-31), carriage among household members (OR a 5.6, 95% CI 1.2 -26), throat (OR a 2.9, 95% CI 1.4 -6.1) or perineal (OR a 2.2, 95% CI 1.1 -4.4) carriage and treatment according to the guideline (nasal ointment and disinfecting body wash only, without oral antibiotics) (OR a 7.4, 95% CI 1.7-32) were all associated with treatment failure in patients with uncomplicated carriage (Table 2) . Among uncomplicated carriers who were treated according to the guideline, only throat carriage remained associated with treatment failure (OR a 3.5, 95% CI 1.8-6.7) ( Table 2 ).
In those with complicated carriage, throat carriage (OR a 4.4, 95% CI 2.3 -8.3) and being ADL dependent (OR a 3.6, 95% CI 1.4 -8.9) were associated with treatment failure, whereas an identified source of acquisition of MRSA compared with an unknown source (OR a 0.4, 95% CI 0.2 -0.8) and addition of the combinations doxycycline/rifampicin (OR a 0.1, 95% CI 0.0 -0.14), doxycycline/fusidic acid (OR a 0.1, 95% CI 0.0 -0.2), co-trimoxazole/rifampicin (OR a 0.1, 95% CI 0.0 -0.2) or trimethoprim/rifampicin (OR a 0.2, 95% CI 0.1-0.6) to topical treatment were associated with treatment success (Table 2) . Among complicated carriers who were treated according to the guideline, throat carriage (OR a 3.6, 95% CI 1.3 -10.3) and the presence of devices (OR a 4.4, 95% CI 1.3 -14.7) were associated with treatment Successful eradication of MRSA in carriers 2421 JAC failure, whereas an identified source of MRSA acquisition compared with an unknown source (OR a 0.3, 95% CI 0.1-0.9) and the antibiotic combinations doxycycline/rifampicin (OR a 0.03, 95% CI 0.01-0.6) and co-trimoxazole/rifampicin (OR a 0.04, 95% CI 0.02 -0.9) compared with the combination doxycycline/fusidic acid were associated with treatment success (Table 2) .
Discussion
MRSA eradication was achieved in 60% of 613 MRSA carriers after a single treatment course, and the relative likelihood of treatment success after the first course was 20% higher if guideline recommendations were followed. Yet, guideline adherence was associated with treatment failure in the subgroup of patients categorized as uncomplicated carriage, but with throat and/or perineal MRSA carriage together with ADL dependency, chronic pulmonary disease and carriage among household members. Addition of an oral antibiotic combination of rifampicin with doxycycline, trimethoprim or co-trimoxazole to topical treatment may further increase treatment success for MRSA carriers with throat and/or perineal MRSA carriage, or with ADL dependency or chronic pulmonary disease. (Table S1 ). Ammerlaan et al.
Furthermore, determining carriage in household contacts when treatment fails is recommended.
Lack of penetration with topical treatment at colonized sites (e.g. tissue and crypts of tonsils) is the most likely explanation for treatment failure in those with throat and perineal MRSA carriage or with chronic pulmonary disease. 12, 13 Another explanation could be that the organism is internalized into throat epithelial cells, where it might be impervious to topical treatment.
14 Similar to results of previous studies, our results underline the importance of carriage in the household, especially when treatment fails. 15 -17 Variables that have been associated with MRSA transmission within households are younger and older age of the household contact, skin lesions and providing healthcare to the index patient. 16, 17 We did not take into account colonization of the environment and pets of MRSA carriers, although strains may cycle between pets and their human acquaintances. 18, 19 Based on ours and other findings, screening of household contacts and simultaneous treatment of identified MRSA carriers should be emphasized, especially when first treatment fails.
This was a pragmatic, observational multicentre study, which had some limitations. The lack of a non-treated or placebotreated control population implies that the results might be confounded by spontaneous clearance of colonization in MRSA carriers without treatment. However, we included only patients that had documented MRSA carriage on two or more timepoints before the start of treatment. Unfortunately, in 83 of 613 carriers, the complexity of carriage could not be determined, since the nasal carriage state was unknown. The outcome for this group was relatively good, suggesting that it contained mainly uncomplicated carriers. Analysis with and without inclusion of these patients did not change the interpretations. However, bias due to selection cannot be completely excluded.
Finally, the approach, efficacy and cost-effectiveness of decolonization in patients with complicated carriage have not been validated. The guideline recommendation for combination therapy with two oral antibiotics in addition to topical treatment with nasal ointment and body wash for complicated carriage was based on a systematic review of randomized clinical trials on decolonization regimens. The strongest evidence exists for combination therapy, with rifampicin being part of it. 7 However, the evidence for this recommendation is weak. Future studies are needed to verify our results.
In conclusion, the results of this study indicate that MRSA carriers can be successfully decolonized and that adherence to the guideline increases the absolute likelihood of treatment success by 20%. Adding systemic antibiotic therapy with two antibiotics (rifampicin with doxycycline, trimethoprim or co-trimoxazole, or fusidic acid with doxycycline) to topical decontamination treatment in patients with extranasal MRSA carriage, chronic pulmonary disease or ADL dependency may further increase treatment success (Figure 1 ).
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